Eli Lilly’s Lepodisiran shows unprecedented reduction in hereditary heart disease risk, sparking Phase 3 trials to validate long-term clinical benefits and redefine treatment for high Lp(a) patients; patients in Israel are participating in Phase 3 trial | Read More in ynet – Culture. Read More in Israel NOWlej.
